The company’s consumer supplement, Tru Niagen®, is the top NAD+ boosting oral supplement in the United States, and its portfolio also includes pharmaceutical-grade intravenous (IV) and ...
ChromaDex reports revenue growth with Niagen leading success, despite risks, its e-commerce surge and profits signal potential. Click to read why CDXC is a Hold.
As part of this transition, the Company will deploy a follow-up announcement ... behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most ...
The rebrand celebrates the company’s clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster ...
Hosted on MSN11mon
ChromaDex (CDXC) Price Target Increased by 9.92% to 6.60ChromaDex Corp. is a science-based integrated nutraceutical company devoted ... Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed ...
Niagen Bioscience™ continuously evaluates and investigates next-generation NAD+ precursors at the forefront of the burgeoning healthy aging category. The company owns and licenses a robust and ...
The company’s revenue for the quarter was $29.1 million, surpassing expectations of $26.78 million. ChromaDex’s flagship product, TRU NIAGEN, contributed $22.7 million to the revenue, which was key in ...
Niagen Bioscience (NAGE) formerly ChromaDex Corp announced the broadening of its NAD+ precursor intellectual property or IP portfolio with the ...
Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results